Swedish Orphan Biovitrum's co-promotion rights for Mimpara sold back to Amgen

09-Nov-2010 - Sweden

Swedish Orphan Biovitrum announced a mutual agreement with Amgen whereby Swedish Orphan Biovitrum will sell back its co-promotion rights in the Nordic countries for Mimpara® (cinacalcet) to Amgen for strategic business reasons. Swedish Orphan Biovitrum will receive an undisclosed payment from Amgen for these rights upfront.

"We have appreciated the long and successful Mimpara partnership with Amgen. We are grateful that they will continue to provide this valuable product to patients in need in the Nordic countries. Swedish Orphan Biovitrum resources that have supported the product will be used to fill resource gaps for products that are moving into the launch phase such as Yondelis, Multiferon and Ruconest." said Kennet Rooth, Head of Marketing and Sales at Swedish Orphan Biovitrum.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances